Valiant Laboratories (NSE:VALIANTLAB) Scaled Net Operating Assets: N/A (As of Mar. 2026)


NSE:VALIANTLAB Valiant Laboratories Ltd NSE:VALIANTLAB
51 GF Score
Price ₹68.00
GF Value ₹103.25
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Valiant Laboratories Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Valiant Laboratories's operating assets for the quarter that ended in Mar. 2026 was ₹4,308 Mil. Valiant Laboratories's operating liabilities for the quarter that ended in Mar. 2026 was ₹1,069 Mil. Valiant Laboratories's Total Assets for the quarter that ended in Dec. 2025 was ₹0 Mil. Therefore, Valiant Laboratories's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was N/A.


Valiant Laboratories Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Valiant Laboratories's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valiant Laboratories Scaled Net Operating Assets Chart

Valiant Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Scaled Net Operating Assets
Get a 7-Day Free Trial 1.05 0.69 0.80 0.82 0.81

Valiant Laboratories Quarterly Data
Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:VALIANTLAB vs ZTS: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valiant Laboratories Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Valiant Laboratories's Scaled Net Operating Assets falls into.


NSE:VALIANTLAB
51GF Score
Valiant Laboratories Ltd NSE:VALIANTLAB
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valiant Laboratories Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Valiant Laboratories's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2026 )
=(Operating Assets (A: Mar. 2026 )-Operating Liabilities (A: Mar. 2026 ))/Total Assets (A: Mar. 2025 )
=(4308.271-1068.796)/4008.575
=0.81

where

Operating Assets(A: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4639.766 - 331.495
=4308.271

Operating Liabilities(A: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1530.915 - 288.907 - 173.212
=1068.796

Valiant Laboratories's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(4308.271-1068.796)/0
=N/A

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4639.766 - 331.495
=4308.271

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1530.915 - 288.907 - 173.212
=1068.796

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued. The current stock price of ₹68.00 is trading 34.1% below its estimated GF Value™ of ₹103.25. GuruFocus considers Valiant Laboratories to be Possible Value Trap.

Key valuation signals for NSE:VALIANTLAB:

  • Scaled Net Operating Assets: N/A
  • GF Value™: ₹103.25 vs. price of ₹68.00 (34.1% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Valiant Laboratories Business Description

Other Exchanges 543998:India
Address Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score

Get the complete analysis for NSE:VALIANTLAB

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹68.00
Price
₹103.25
GF Value